POLATUZUMAB VEDOTIN-PIIQ | B761121 | GENENTECH
No 12-year reference-product exclusivity is listed in the Purple Book, and the reference product was first approved Jun. 10, 2019 — before BPCIA (March 23, 2010), so any 12-year exclusivity has long expired.
Full-label vs. best-skinny biosimilar entry
| Scenario | Date | Status | Controlling |
|---|---|---|---|
| Best-skinny entry (floor) | Open now | Open now | no live licensure floor |
| Full-label entry | Apr. 19, 2030 | 3y 5mo remaining | carveable orphan wall |
Minimal carve: Dropping the orphan-walled indication(s) (protected through 2030-04-19) advances biosimilar entry from the full-label date to now (no remaining licensure floor).
Carve frontier · drop each orphan-walled indication to advance entry
| Drop this orphan-walled indication | Walled through | → Entry advances to |
|---|---|---|
| treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) and who have an International Prognostic Index score of 2 or greater(label indication #1) | Apr. 19, 2030 | Open now(12-yr RPE floor) |
Each rung drops one orphan-designated indication (sourced from the FDA Orphan Drug Product designation database and matched to the reference label); dropping the latest-walled indication advances biosimilar entry to the next constraint, until every orphan wall is carved and entry reaches the RPE floor.
Carveable orphan wall · Apr. 19, 2030
Orphan-drug exclusivity runs past the licensure floor, but it walls only its specific orphan-designated indication(s). A biosimilar can omit those indications (a “fewer-than-all-conditions” carve-out) and be licensed for the rest now, then add the protected indication back by supplement once the orphan period expires. It is not a licensure gate for the other indications.
Marketing-entry ceiling (litigation risk)
Patents do not gate FDA licensure of a biosimilar — FDA licenses biosimilars (full or carved label) without adjudicating any patent. These are a practical marketing-entry ceiling resolved in the § 262(l) patent dance and ordinary litigation. A formulation/compound patent caps practical skinny entry via litigation (Regeneron v. Mylan); a method-of-use patent is carveable and gates nothing.
Latest formulation/compound patent 12371507(composition)· AI-discovered, not Purple-Book-listed · relevance 75/100. This caps practical skinny-label entry; it does not move the licensure floor above.
36 formulation/compound (cap skinny entry) · 4 method-of-use (carveable — gate nothing) · 10 device/diagnostic/manufacturing
| Patent | Class | Expiration | Source |
|---|---|---|---|
| 12371507 | Formulation/compound | Jul. 24, 2045Active | Discovered |
| 12291575 | Method-of-use (carveable) | May. 1, 2045Active | Discovered |
| 12257281 | Formulation/compound | Mar. 20, 2045Active | Discovered |
| 12195547 | Method-of-use (carveable) | Jan. 9, 2045Active | Discovered |
| 12090211 | Formulation/compound | Sep. 12, 2044Active | Discovered |
| 12023368 | Formulation/compound | Jun. 27, 2044Active | Discovered |
| 12016842 | Method-of-use (carveable) | Jun. 20, 2044Active | Discovered |
| 11987638 | Other | May. 16, 2044Active | Discovered |
| 11944689 | Formulation/compound | Mar. 28, 2044Active | Discovered |
| 11873330 | Formulation/compound | Jan. 11, 2044Active | Discovered |
| 11844839 | Other | Dec. 14, 2043Active | Discovered |
| 11833216 | Formulation/compound | Nov. 30, 2043Active | Discovered |
| 11712480 | Other | Jul. 27, 2043Active | Discovered |
| 11666581 | Formulation/compound | Jun. 1, 2043Active | Discovered |
| 11661438 | Other | May. 25, 2043Active | Discovered |
Showing 15 of 50 patents (latest expirations).
Disclaimer: Identifying an available carve-out is not a prediction that FDA will approve the particular carved label, nor that marketing it is free of infringement risk. For biologics, availability turns on exclusivities, not patents: FDA licenses a biosimilar (full or carved label) without adjudicating any patent, and patent disputes run through the § 262(l) patent dance and ordinary litigation, outside this availability view.
Top 50 of 227 AI-discovered patents by relevance.
No patent or exclusivity listings for this strength.